Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 2007

View Archived Issues

Novartis rounds up 2006

Novel metabolic drugs described in recent patent literature

Novel antiinfective agents disclosed in recent patent literature

Recent patents disclose novel therapeutic options for neurological disorders

ThermoDox phase I data suggest manageable toxicity; patient accrual continues

Kiadis acquires research assets related to Wnt-signal transduction pathway

elbion acquires product candidates from DrugAbuse Sciences

Coley suspends independent development of Actilon for HCV

Milestone in Acumen and Merck's Alzheimer's collaboration

Medarex and Compugen collaborate on therapeutic antibody development

MN-305 studied for insomnia in new phase II trial

New phase II trial studies Davanat with 5-FU for advanced biliary cancer

NT-proBNP Test commercially launched in Europe

Launch of pharmacogenetic test for clozapine-induced agranulocytosis

Positive phase III findings for Akten in ocular anesthesia

Affectis inlicenses cimicoxib for CNS disorders

Pivotal phase III grass allergy trial of Pollinex Quattro begins

GSKbeta/catenin pathway accounted for radiosensitization of pancreatic cancer

U.K. clearance for phase III trials of CUV-1647 in polymorphous light eruption

University of Illinois researchers funded to develop new bipolar disorder drug

FDA action letter received for immunosuppressant FK-506 MR

Clinical data on AZD-2171 presented at GI Cancer Symposium

Novel sigma2 receptor ligands may be useful against pancreatic cancer

Clinical update on NV-1020

Notch signaling disruption sensitizes colon cancer cells to oxaliplatin

Approvable letter for Pristiq for major depressive disorder

Fresenius seeks approval for PhosLo in patients with Stage 4 chronic kidney disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...